Skip to main content
. 2014 Dec;4(4):669–678. doi: 10.1086/678512

Table 3.

Response to pulmonary arterial hypertension (PAH) drug therapy

PAH–No CV group (n = 43) PAH-CV group (n = 69) P value for improvement vs. no improvement
Improvement 16 (37) 11 (16) 0.002/0.027a
No improvement 27 (63) 58 (84)
 Stable 14 (33) 31 (45)
 Worsening 13 (30) 27 (39)
Note

Data are no. (%). CV: cardiovascular risk factors.

a

After adjustment for age.